A changing healthcare landscape

Advances in AI, data infrastructure, and biological understanding are fundamentally changing how healthcare products are developed and deployed.

This shift enables a new class of companies — platforms that can translate complex biology into real clinical solutions.

Many of these companies emerge in Israel, yet remain underfunded at early stages due to their technical and regulatory complexity.

Averis was created to invest precisely at this point.

Our focus includes:

• Deep Life Science & GenBio
  Therapeutics, AI-native biology, diagnostics, and modality-driven platforms

• Bio-Enabled Platforms & Infrastructure
  Drug discovery tools, bio-manufacturing, process analytics, data layers

• HealthTech
  Clinical enablement, diagnostics-adjacent software, regulated care infrastructure

How we think and operate

Early healthcare investing often fails because complexity is treated as something to avoid.

Our advantage lies in working within complexity, not around it.

• We engage early with clinical reality, not just technology.

• We apply regulatory and adoption thinking from the start.

• We work closely with founders during early, execution-critical phases.

• We access non-consensus opportunities that are often overlooked by mainstream venture capital.

A Strategic European Bridge

Alongside our activity in Israel, Averis maintains a strategic corridor into the DACH healthcare ecosystem.

This corridor provides direct access to high-quality, often oversubscribed investment rounds, where allocation is driven by trusted relationships rather than inbound access.

In practice, this enables:

• Investing alongside experienced European healthcare investors

• Participation in competitive rounds with limited capacity

• Early exposure to companies and opportunities not broadly marketed

The DACH corridor is a structural access advantage—enhancing sourcing quality and allocation certainty—without prescribing geography, timing, or outcomes for portfolio companies.

How we work with founders

We combine early institutional capital with hands-on involvement through critical early stages.

Our role is to help companies:

• Make better early decisions

• Build toward real adoption

• Develop with long-term relevance in mind

We aim to be disciplined, supportive, and long-term partners.